Compare Adaptive Biotechnologies Corp (ADPT) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nutrien Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Nutrien Ltd trades at $66.46 (market cap $31.34B). The key difference: Nutrien Ltd is far larger — about 9.4× Adaptive Biotechnologies Corp's market cap, and Nutrien Ltd pays a 3.37% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NTR | |
|---|---|---|
Market Cap | $3.33B | $31.34B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $83.94 |
52-Week Low | $10.24 | $53.64 |
Enterprise Value | $3.19B | $44.51B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Nutrien (NTR) trades at $65.32, up 0.4% with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with Q1 2026 earnings beating estimates and revenue growth projected to $27.8B in 2026. Analyst consensus is strongly bullish with a $81.86 price target, representing 25% upside potential from current levels.
NTR presents value with attractive valuation multiples (P/E 13.14, P/S 1.12) and strong fertilizer demand fundamentals. Key risks include volatile input costs, supply chain disruptions, and debt refinancing needs. The stock offers dividend income with recent $0.55 payout, positioning it as a compelling agribusiness investment amid global food security trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
